A MULTICENTER, OPEN LABEL, RANDOMIZED, PHASE 2 STUDY OF VENETOCLAX AND AZACITIDINE PLUS CUSATUZUMAB VERSUS VENETOCLAX AND AZACITIDINE ALONE IN NEWLY DIAGNOSED AML PATIENTS WHO ARE NOT CANDIDATES FOR INTENSIVE THERAPY